Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.
Zacks Investment Research on MSN
Figma stock plunges 27.4% YTD: Should investors buy, sell or hold?
Figma FIG shares have lost 27.4% year to date (YTD), underperforming the Zacks Internet - Software industry’s decline of 6.2% ...
12don MSN
A stock-market plunge is the only thing that can stop bond yields from surging, a research firm says
The outlook for global stocks is "poor" amid concerns about inflation, BCA Research said, adding that a material drop in ...
Shares in payment processor Wise are down more than 10% on news that it is being investigated in Belgium for potential ...
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today ...
1mon
Top economist Gary Shilling says a recession and a deep stock-market plunge are likely by year-end
Legendary economist Gary Shilling says the S&P 500 could end tumble by as much as 30% this year as stocks get punished for ...
The stock market has been soaring since April, with the Dow Jones Industrial Average (DJINDICES: \^DJI), S&P 500 (SNPINDEX: \^GSPC), and Nasdaq Composite (NASDAQINDEX: \^IXIC) all hi ...
Qualcomm (QCOM) stock plunged up to 10% after Nvidia unveiled RTX Spark, a Windows on Arm chip competing directly with ...
Erasca disclosed a potentially treatment-related death in its Phase 1 ERAS-0015 trial, and its stock plummeted 48% on the ...
Gap shares fell sharply Friday after the retailer posted sales that missed analysts' estimates and lowered its outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results